An experimental study of the combination of paclitaxel therapy and ezrin-siRNA treatment in meta-static liver cancer
10.3760/cma.j.issn.1007-8118.2014.02.014
- VernacularTitle:紫杉醇化疗联合ezrin-siRNA治疗转移性肝癌的实验研究
- Author:
Fei GAO
;
Bo HUANG
;
Hao ZOU
;
Xiaowen ZHANG
- Publication Type:Journal Article
- Keywords:
Liver cancer;
ezrin;
Paclitaxel;
Drug therapy;
RNA interference;
Gene therapy
- From:
Chinese Journal of Hepatobiliary Surgery
2014;20(2):133-136
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate paclitaxel and ezrin-siRNA therapy for metastatic liver cancer.Methods Human metastatic liver cancer cells MHCC97-H were divided into four groups in vitro and in vivo,including control cells,exposure to paclitaxel alone,ezrin-siRNA alone,and the combination of paclitaxel and ezrin-siRNA.Nude mice lung lesions were formed by tail vein injection of tumor cells.The tumor cells'apoptosis rate,wound healing ability,the ability to cross an artificial membrane,and the numbers of metastatic lung lesions were measured.Results The apoptosis rate in normally cultured MHCC97-H tumor cells was 2.52％,compared to the other three groups at 11.66％,2.35％,7.38％ respectively.The wound healing ability was best in the negative control and weakest in cells treated with combination paclitaxel and ezrin-siRNA.The numbers of cells which could cross the artificial membrane in the negative,paclitaxel,ezrin-siRNA,and combination paclitaxel and ezrin-siRNA group were 52.5 ± 3.9,32.2 ± 3.2,26.6 ± 2.4,and 19.4 ± 1.1 respectively.The numbers of metastatic lung lesions in the nude mice (n =40) were 12.5 ±2.4,8.2 ± 1.5,7.0 ± 1.3,and 3.8 ± 0.3 respectively.Conclusions The ezrin-siRNA combined with paclitaxel therapy demonstrated a greater efficacy over single agent therapy for depressing liver cancer growth,motility,aggression,and metastasis in vitro and in vivo.
